Author(s)

Yuan Chen, Lanqing Liu, Yuemo Wang

Corresponding Author

Lanqing Liu

ABSTRACT

Cancer threatens the health of human beings around the world because of its high incidence, high fatality rate, and difficulty in treatment. Traditional treatment methods are mostly surgical treatment. However, the recurrence rate of cancer after surgery is still high. In recent years, more and more cancer treatment methods have emerged. Radiation therapy, chemotherapy, etc. Among them, immunotherapy is a hot topic of research in recent years. Pembrolizumab (Keytruda) is an immunotherapy drug used in cancer. A large number of studies have shown that keytruda is superior to conventional chemotherapy in all aspects, both as a single agent and in combination. Data show that keytruda is effective in NSCLC, which is resistant to standard chemotherapy and has rarely been treated before. In this review, we first briefly introduced CAR-T therapy and keytruda, focusing on analyzing and summarizing various experimental data related to keytruda and other oncology drugs. With the gradual understanding of the pathogenesis of tumors and the mechanism of action of various treatment methods, breakthroughs in tumor immunotherapy are expected to accelerate in the next few decades.

KEYWORDS

Immunotherapy, Pembrolizumab (Keytruda), CAR-T, Non-small-cell lung carcinoma (NSCLC)